Montara Therapeutics received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop a Parkinson’s disease treatment designed to work primarily in the brain and minimize effects on the rest of the body. The new drug will target the mTOR biological pathway.
News
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded Lysoway Therapeutics $3.4 million in funding to support the development of an investigational therapy targeting the TMEM175 protein. The grant is part of the foundation’s Parkinson’s Disease Therapeutics Pipeline Program, which aims to accelerate the development of potential…
More than 2,000 potential participants have been identified for screening in a Parkinson’s clinical trial, thanks to the Parkinson’s Foundation‘s PD Trial Navigator matching program. The Phase 2 trial (NCT06680830), known as NEULARK, is evaluating Neuron23‘s experimental therapy, NEU-411, in up to 150 people with early-stage,…
Patient enrollment has started in a Phase 2a clinical trial evaluating Jotrol, an oral formulation of resveratrol developed by Jupiter Neurosciences as a treatment for Parkinson’s disease, the company has announced. The RESET trial (NCT07592767) is recruiting up to 30 patients at three sites in…
A University of Minnesota Medical School team has received a $6 million grant to design mouse models for the study of genetic variants linked to Parkinson’s disease. “These models could help us better understand how Parkinson’s disease works and support testing of potential therapies in early stages of research,”…
Biogen and Denali Therapeutics have ended their clinical development of BIIB122 for people with idiopathic Parkinson’s disease after the experimental therapy failed to slow disease progression in a Phase 2b trial. The decision follows results from the Phase 2b LUMA study (NCT05348785), which compared BIIB122 (also…
A team of researchers in Germany has developed an immuno-infrared sensor (iRS) designed to detect misfolded alpha-synuclein, a protein linked to Parkinson’s disease, in body fluids including blood and the fluid that surrounds the brain and spinal cord. The researchers say the technology could one day support earlier diagnosis,…
Herantis Pharma will use a system based on smartphone technology to measure symptom changes in a Phase 2 trial testing its Parkinson’s disease treatment HER-096. Researchers will use Indivi’s digital biomarker platform alongside conventional clinical assessments to help researchers detect early changes in motor and cognitive function in…
The first participant has been dosed in Vertero Therapeutics’ Phase 1b clinical trial testing VT-5006, an investigational, gut-directed oral small molecule being developed for Parkinson’s disease. The Phase 1b clinical trial (NCT07310264) is still recruiting adults ages 40-80 with early- or moderate-stage…
A pivotal clinical trial testing the light therapy device Celeste for Parkinson’s disease has wrapped up, with the last enrolled participant completing the study’s final visit. That’s according to a company press release from device developer Photopharmics, which called the completion of the…
Recent Posts
- Scenic joins LITE program to test Parkinson’s treatment approach
- Could a levodopa pump help reduce my dad’s ‘off’ periods?
- High-resolution PET scanner may aid Parkinson’s research, diagnosis
- The day NASCAR got a win over my uncle’s Parkinson’s disease
- Free-water MRI builds more complete picture for Parkinson’s diagnosis